Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03152292 · ClinicalTrials.gov registry record
The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study
A clinical trial, sponsored by ACADIA Pharmaceuticals.
- Terminated
- Registry status
- 764
- Enrollment target
NCT03152292: Clinical Trial study, sponsored by ACADIA Pharmaceuticals.
NCT03152292 is a clinical trial that was terminated before completion, run by ACADIA Pharmaceuticals. The registered enrollment target is 764 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03152292 was terminated before completion, sponsored by ACADIA Pharmaceuticals.
- TERMINATED
- Registry status
- 764 participants
- Enrollment target
Study Summary
To examine the current disease progression of PDP, the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the burden of the condition on patients and their caregivers
Primary Outcome
Describe the safety and effectiveness of antipsychotic therapies and other treatment approaches in the management of PDP. Describe comparative clinical, economic, and humanistic outcomes of treatment approaches for both patients and caregivers, in the context of real-world medical practice settings.
Interventions
- OTHER Real-world, non-interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 764 participants |
| Start Date | 2017-03-30 |
| Est. Completion | 2021-03-08 |
Why NCT03152292 stopped before completion
NCT03152292 is an observational study that tracks outcomes without assigning an intervention. The registered 764 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Real-world, non-interventional is the first listed.
NCT03152292 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03152292 about?
NCT03152292 is a clinical study titled "The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study". To examine the current disease progression of PDP, the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the burden of the condition on patients and their caregivers
What is the current status of trial NCT03152292?
This trial is currently terminated. The enrollment target is 764 participants. The study started on 2017-03-30. Estimated completion is 2021-03-08.
What interventions are being tested in trial NCT03152292?
The interventions under investigation include: Real-world, non-interventional (OTHER).
Who is sponsoring clinical trial NCT03152292?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578665 · 764 participants · NA
Human-like Robotic Controllers for Enhanced Motor Learning
- NCT05579366 · 764 participants · Phase 1
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- NCT03789552 · 765 participants · Phase 3
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina
- NCT07195591 · 766 participants · Phase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI